Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03771651 · ClinicalTrials.gov registry record · Early Phase 1
Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube
A Early Phase 1 study of Fallopian Tube Cancer and Fallopian Tube Infection, sponsored by University of Oklahoma.
- Active
- Registry status
- Early Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT03771651 is a Early Phase 1 study of Fallopian Tube Cancer and Fallopian Tube Infection that is active but no longer recruiting, run by University of Oklahoma. The registered enrollment target is 18 participants, below the 256-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03771651, a Early Phase 1 study of Fallopian Tube Cancer and Fallopian Tube Infection, is active but no longer recruiting, sponsored by University of Oklahoma.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the impact of low dose aspirin on normal fallopian tube fimbriae in women who have surgery to have their fallopian tubes removed. Participants will take a low dose of aspirin for 2 weeks before their surgery. A portion of the removed fallopian tubes will also be collected for future research and routine pathology purposes.
Conditions Studied
Interventions
- DRUG Aspirin 81 mg
Study Locations (1)
Oklahoma
- Stephenson Cancer Center, University of Oklahoma Health Sciences Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2026-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03771651
The ClinicalTrials.gov registry entry for NCT03771651 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 256-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (93% lower). The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Fallopian Tube Cancer appearing as the primary indexed condition, and to 1 intervention - of which Aspirin 81 mg is the first listed.
NCT03771651 reports 1 study location spanning 1 distinct geographic area - top geographies include Oklahoma.
Frequently Asked Questions
What is clinical trial NCT03771651 about?
NCT03771651 is a clinical study titled "Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube". This study will evaluate the impact of low dose aspirin on normal fallopian tube fimbriae in women who have surgery to have their fallopian tubes removed. Participants will take a low dose of aspirin for 2 weeks before their surgery. A portion of the removed fallopian tubes will also be collected fo...
What is the current status of trial NCT03771651?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2019-03-01. Estimated completion is 2026-12.
What conditions does trial NCT03771651 study?
This clinical trial studies the following conditions: Fallopian Tube Cancer, Fallopian Tube Infection.
What interventions are being tested in trial NCT03771651?
The interventions under investigation include: Aspirin 81 mg (DRUG).
Who is sponsoring clinical trial NCT03771651?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03771651 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fallopian Tube Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Using Aspirin to Improve Immunological Features of Ovarian Tumors
RECRUITING · Early Phase 1
-
Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer
COMPLETED · Early Phase 1
-
A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers
COMPLETED · Early Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.